Injectable division
Retatrutide
AClass-leading
Eli Lilly · certified
vs
Injectable division
Survodutide
LaggingC
Boehringer Ingelheim · certified
21% · leads
Efficacy
8%
Notable (+6.4) · gentler
Tolerability
Heavy (+17.3)
Subcutaneous injection
Route
Subcutaneous injection
None
Food / water rule
None
Refrigerated
Storage
Refrigerated
The call: Retatrutide leads on efficacy: class leading to Survodutide's lagging (21% vs 8%). Retatrutide is the easier of the two to stay on (Notable vs Heavy). One caveat: Retatrutide's lead rests on a number that is topline, not yet peer-reviewed and not yet approved, so treat it as provisional until it is confirmed; Survodutide is the published benchmark.
Standalone, this page carries its own key: Efficacy = % body weight lost vs placebo, on the conservative estimand that counts everyone. Tolerability = AE-discontinuation over placebo (Mild 1 to 5 · Notable 5 to 10 · Heavy over 10 points). Winners are called only across a tier or band boundary; within one, the drugs are effectively tied. The side marked leads or gentler wins that axis.
Retatrutide verdict · Survodutide verdict · How this is scored